Nerivio Study Clears Path for Migraine-Diabetes Patients

BRIDGEWATER, N.J. – February 24, 2026 – For the estimated 4.5 million Americans navigating the complex dual diagnosis of migraine and diabetes, managing their health has long been a delicate balancing act. A landmark study published today in the peer-reviewed Journal of Clinical Medicine offers a significant breakthrough, providing crucial reassurance that a leading drug-free migraine therapy can be used safely alongside essential diabetes monitoring technology.

The study, sponsored by neuromodulation therapeutics company Theranica, confirms that its Nerivio® wearable for migraine treatment does not interfere with the accuracy of contemporary Continuous Glucose Monitoring (CGM) systems. This is the first clinical study to directly evaluate the concurrent use of a neuromodulation migraine therapy with CGM devices, addressing a critical question for both patients and healthcare providers in an increasingly connected health ecosystem.

A Breakthrough for a Dual Diagnosis

Living with both migraine and diabetes presents unique challenges. Uncontrolled blood sugar can be a trigger for headaches, while the stress and pain of a migraine attack can, in turn, impact glucose levels. Furthermore, treatment options can be fraught with complications. Many common pharmacological migraine treatments carry metabolic or cardiovascular considerations that can be problematic for individuals with diabetes, pushing patients and their doctors toward non-drug alternatives.

However, the rise of wearable medical technology introduced a new concern: digital interference. Both the Nerivio® device—a smartphone-controlled band worn on the arm that uses Remote Electrical Neuromodulation (REN) to treat and prevent migraine—and modern CGM systems from companies like Abbott and Dexcom rely on Bluetooth® connectivity to transmit data to smartphone apps. The possibility of one device disrupting the other has been a persistent, unanswered question.

This new study provides a definitive answer, removing a significant barrier to care. By validating the safe co-use of these devices, it empowers patients to manage their migraines effectively with a drug-free option without compromising the integrity of their critical, real-time glucose data.

“Migraine treatment can be especially complex for individuals with diabetes because many pharmacologic options carry metabolic or cardiovascular considerations,” noted Dr. Richelle deMayo, a contributing author of the study and chief medical information officer at Connecticut Children's Research Institute. “As connected health technologies continue to expand, confirming safe multi-device operation is increasingly important for real-world patient care.”

Inside the Clinical Validation

The research, titled “Simultaneous Use of Continuous Glucose Monitoring (CGM) Systems and the Remote Electrical Neuromodulation (REN) Wearable for Patients with Comorbid Diabetes and Migraine,” employed a rigorous methodology to ensure its findings were robust. The interventional study involved 21 adults with diabetes who were regular users of the most common CGM systems in the United States: Abbott’s FreeStyle Libre® 2 and 3, and Dexcom’s® G6 and G7.

During a full 45-minute Nerivio® treatment session, researchers collected CGM readings during phases when the device’s electrical stimulation was active and when it was paused. The primary goal was to detect even minor deviations in glucose readings, measured by a stringent statistical benchmark known as the Mean Absolute Relative Difference (MARD), with a predefined success threshold of 5.0%.

The results were conclusive. The study found a median deviation of just 1.6%, falling well below the benchmark and demonstrating no clinically significant impact on CGM accuracy. All 21 participants individually met the threshold criterion. Importantly, the study observed zero instances of Bluetooth® disruptions, missed data transmissions, device malfunctions, or adverse events, confirming stable performance for both the Nerivio® wearable and the CGM system during simultaneous operation.

“These findings demonstrate that the Nerivio REN wearable and CGM systems can be used together without compromising glucose data integrity—which is critically important for people managing both migraine and diabetes,” said Christina Treppendahl, a certified headache medicine specialist at Theranica who initiated and co-authored the study.

The Growing Ecosystem of Connected Health

The study's implications extend far beyond this specific use case, signaling a maturing landscape for connected health. The global market for connected medical devices is valued at over $48 billion and is projected to grow substantially as more patients rely on wearables for remote monitoring and chronic disease management. This proliferation of technology makes interoperability and compatibility not just a convenience, but a core safety requirement.

Theranica's research sets a new precedent for device manufacturers, highlighting the importance of proactively validating how their products function within a patient's broader technology ecosystem. For a patient with diabetes and migraine, a typical day might involve a CGM, an insulin pump, a blood pressure monitor, and a migraine treatment device—all potentially communicating with a single smartphone. Ensuring these devices can coexist without interference is paramount.

By undertaking this study, Theranica has provided a blueprint for how companies can build trust and confidence among both clinicians and patients, demonstrating a commitment to real-world usability and safety that is essential for the future of digital medicine.

A Strategic Move in a Competitive Market

In the competitive market for non-pharmacological migraine treatments, this study gives Nerivio® a distinct advantage. While other neuromodulation devices exist—such as Cefaly (eTNS), gammaCore (nVNS), and Relivion MG (eCOT-NS)—Theranica is the first to provide clinical data specifically addressing CGM compatibility. This positions Nerivio® as the clear choice for the millions of migraine sufferers who also manage diabetes.

The finding builds on Theranica's significant market momentum. The company recently announced that Nerivio® has achieved coverage for approximately 130 million lives in the U.S., placing it on par with major drug classes and signaling a shift in payer acceptance of REN as a mainstream therapy. This new compatibility data will likely accelerate adoption within a large and underserved patient segment.

By focusing on the specific needs of patients with complex comorbidities, Theranica is not only expanding its addressable market but also reinforcing its brand as a leader in clinically-grounded, patient-centric innovation. As medicine becomes increasingly personalized, this focus on safe integration into patients' lives provides a powerful differentiator.

“Our goal is not only to provide effective drug-free migraine treatment, but to ensure our technology integrates safely into patients' broader care ecosystems,” Treppendahl stated, underscoring the company’s philosophy. This commitment helps remove a key barrier for people managing multiple chronic conditions, paving the way for a more integrated and less burdensome approach to their daily health management.